Steps to disable Ad Blocker on your browser

In order to serve content on our website, we rely on advertising revenue which helps us ensure that we continue to serve high quality, unbiased journalism. From our end, we will aim to show clean and unobtrusive ads to provide you with a great browsing experience. Please follow the steps below, and once done, please refresh your page.

Using AdBlock Plus

Click on the AdBlock Plus icon on the top right of your browser

A drop-down menu will appear with a check mark followed by Enabled on this site

Click the button to until the text reads Disabled on this site

Refresh the page or click Refresh, to access LiveMint.com

Using Chrome adblock extension

Click on the hand icon for adblock extension, on the top right corner of your browser

A drop-down menu will appear

Click the Don't run on pages on this domain option on the drop down

Once clicked a settings popup will appear.

Click Exclude

Refresh the page or click Refresh, to access LiveMint.com

Using AdBlock Plus

Click on the AdBlock Plus icon on the top right of your browser

A drop-down menu will appear

Click the Disabled on LiveMint.com option on the drop down

Refresh the page or click Refresh, to access Times of India

Firefox "Private Window" runs its own version of adblock. You will receive an adblock detection screen on private window, even if you are not running any adblock plugins. In this case, you will need to open LiveMint.com on your standard Firefox window.

Go to the Settings app on the main screen

Click on the Safari button

From Menu click Content Blockers

You will see your blocker enabled. Slide button to the left to disable.

Return to your Safari browser and refresh the page or click Refresh, to access LiveMint.com

Click on the AdBlock Plus icon on the bottom right hand side of your browser

A drop-down menu will appear

Click the Disable on LiveMint.com option on the drop down

Refresh the page or click Refresh, to access LiveMint.com

Go to the Settings app on the main screen

Click on the Safari button

From Menu click Content Blockers

You will see your blocker enabled. Slide button to the left to disable

Return to the Safari browser and refresh the page or click Refresh, to access LiveMint.com

Sign Up

Aurobindo has shareholder approval to raise Rs2,100 crore through a sale of shares, which it intends to use for acquisitions. Photo: Bloomberg

Hyderabad: Aurobindo Pharma Ltd is scouting for acquisitions in Europe to gain a foothold in the market.

“I would not comment on the specifics, but as we had mentioned in the past also, it is predominantly two large areas—one is in terms of market expansion and one is in terms of newer platforms in terms of technology,” managing director N. Govindarajan told analysts in a conference call on 16 November.

“From a market expansion perspective, if we really look at opportunities across the globe, it would be more in Europe than in the US for a simple reason that our pipeline is so strong in the US. As far as Europe is concerned, we would like to really look at something having better margin because it will improve our overall European Ebitda (earnings before interest, tax, depreciation and amortization,” Govindarajan said.

The Europe push comes amid Aurobindo’s successful turnaround of the money-losing Western European commercial operations of Irish drug maker Actavis Plc, which it bought for €30 million in 2014.

The Economic Times on 3 November reported that Aurobindo had expressed preliminary interest in acquiring Portuguese drug maker Generis Farmaceutica for about $200 million.

Generis makes anti-infective, respiratory, anti-diabetes and dermatology drugs, besides a contract manufacturing and analytical services arm. It generated sales of around $60 million last year.

Phone calls and emails to a spokesperson for Aurobindo did not elicit a response.

Aurobindo was also in the race to acquire Israel-based Teva Pharmaceutical Industries Ltd’s UK assets, but was outbid by Ahmedabad-based Intas Pharmaceuticals Ltd.

Aurobindo has shareholder approval to raise Rs2,100 crore through a sale of shares, which it intends to use for acquisitions.

Analysts say buyouts in Europe makes sense as Aurobindo has been building dedicated plants in India to source drugs for its Western European generics business.

“Inorganic expansion in Europe helps Aurobindo to quickly ramp up its sales and margins, as the company is well integrated with robust low-cost manufacturing base in India,” said an analyst who didn’t want to be named, citing company policy.

The company is spending about Rs900 crore as part of its capital expansion—that includes an oral finished dosage facility for European markets in Visakhapatnam, Andhra Pradesh.